Aerocrine AB and Microsoft collaborate to test secure, cloud-based remote medical device monitoring.
Solna (Sweden) – September 29, 2014 – Aerocrine AB (OMX Nordic Exchange: AERO), the innovator of NIOX® brand medical devices announces today a collaboration with Microsoft. Aerocrine’s devices are used by physicians to measure Fractional exhaled Nitric Oxide (FeNO), a biomarker for allergic, airway inflammation which is linked with Asthma. The collaboration will utilize Microsoft’s secure cloud services to transmit device telemetry data from physician and company sites in Sweden, UK and US back to Aerocrine for analyses. Aerocrine’s goal is to use this information to deploy its field resources for customer service and sales support in the future. Microsoft chose Aerocrine due to its device technology, global reach and commitment to progressing human health management.
Aerocrine is committed to improving the management of inflammatory airway disease and the quality of patients’ lives. One of the world’s most common diseases, asthma affects 8 to 10 percent of the global population. Since the disease has no cure, proper diagnosis and management are important to optimize the treatment of a patient’s asthma. Using an Aerocrine FeNO-testing device offers several advantages for patient care. The physician can accurately identify the patients, the type of medication they should receive and use the device to monitor the patients’ progress helping them to maintain adequate control and minimize exacerbations.
“The ability to collect vital telemetry data from deployed devices has been a key objective of ours. A cloud-based solution allowing us to collect data on device performance in real-time helps us to be more proactive in our customer support and ensure that our NIOX devices help the physicians deliver the best possible outcome for the patient,” says Scott Myers, CEO of Aerocrine.
Microsoft and Aerocrine are working together on this pilot project because of the unique ability of Aerocrine’s devices to generate data at the point of care. This proof of concept will be conducted this fall and will collect data from Aerocrine devices deployed in Sweden, the UK and the United States. Microsoft will connect the Aerocrine devices to its secure cloud analytics platform, Microsoft Azure in the first phase to demonstrate the secure and accurate transmission of telemetry data.
“We are excited to work with Aerocrine on this project as part of the CityNext, Healthier Cities initiative to show the potential of new technology to drive productivity and patient safety as we move towards a mobile-first and cloud-first world,” says Mathias Ekman, Industry Marketing Development Manager at Microsoft Sweden.
For more information, contact:
Scott Myers, Chief Executive Officer, Aerocrine AB, +46 768 788 379, +1 970 368 0336
Mats Carlson, VP Global Business Operations, Aerocrine AB, +46 705 34 89 89
About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO® (EU) Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007. For more information, please visit www.aerocrine.com and www.niox.com.
Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 16:55 on September 29, 2014.